Cited by 190Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsFerroptosis and cancer prognosis

The DOI matches its Crossref record; 180 of the 184 references it cites were found in a registry or an index.

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Open access

Qiao, Meng, Jiang, Tao, Liu, Xinyu, Mao, Shiqi, Zhou, Fei, Li, Xuefei, Zhao, Chao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Zhou, Caicun·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2021.04.003

Open this paper in CoChat — free account

Abstract

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., programmed cell death ligand-1 expression, tumor mutation burden), which have been validated in EGFR-wild type NSCLC, however, are not efficacious in EGFR-mutated tumors, suggesting the unique characteristics of tumor microenvironment of EGFR-mutated NSCLC. Here, we first summarized the clinical evidence on the efficacy of ICIs in patients with EGFR-mutated NSCLC. Then, the cancer immunogram features of EGFR-mutated NSCLC was depicted to visualize the state of cancer-immune system interactions, including tumor foreignness, tumor sensitivity to immune effectors, metabolism, general immune status, immune cell infiltration, cytokines, and soluble molecules. We further discussed the potential subpopulations with EGFR mutations that could benefit from ICI treatment. Lastly, we put forward future strategies to adequately maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the upcoming era of combination immunotherapies.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.04.003

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citation
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,478
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Show all 184 references

Research works printed but not linked: 3

Garon, 2015, Prior TKI therapy in NSCLC EGFR mutant patients associates with lack of response to anti-PD-1 treatment, J Thorac Oncol, 10
Qiao, 2021, MA13.06 Deciphering the characteristics of tumor microenvironment in EGFR-mutated non-small cell lung cancer, J Thorac Oncol, 16
Le, 2019, Abstract 5028: Characterization of the tumor immune microenvironment in treatment-nave EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype, Proceedings: AACR Annual Meeting

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
Self-citation
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 95
Self-citation
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 88
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Bradley, J. D., Sugawara, S., Lee, K. H., Ostoros, G., Demirkazik, A., Zemanová, M., Sriuranpong, V., Gelatti, A. C. Z., Menezes, J. J. D., Żurawski, B. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00036 · Cited by 87
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Zhao, Y., He, Y., Wang, W., Cai, Q., Ge, F., Chen, Z., Zheng, J., Zhang, Y., Deng, H., Chen, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00379-6 · Cited by 76
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Garg, P., Singhal, S., Kulkarni, P., Horne, D. A., Malhotra, J. D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144189 · Cited by 77
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
Kim, C. G., Kim, G., Kim, K. H., Park, S., Shin, S., Yeo, D., Shim, H. S., Yoon, H. I., Park, S. Y., Ha, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002780 · Cited by 57
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52
Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC
Ernst, S. M., Mankor, J. M., van Riet, J., von der Thüsen, J. H., Dubbink, H. J., Aerts, J. G. J. V., de Langen, A. J., Smit, E. F., Dingemans, A. C., & Monkhorst, K. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.030 · Cited by 49
Progress of Nanomaterials in Photodynamic Therapy Against Tumor
Chen, L., Huang, J., Li, X., Huang, M., Zeng, S., Zheng, J., Peng, S., & Li, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920162 · Cited by 40
Self-citation
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
Xiao, G., Li, L., Tanzhu, G., Liu, Z., Gao, X., Wan, X. H., Xiao, D., Chen, L., Xia, X., & Zhou, R. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006243 · Cited by 38
EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lü, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05456-5 · Cited by 38
Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO
Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09296-8 · Cited by 32
Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
Zhang, J., Vokes, N. I., Li, M., Xu, J., Bai, H., Wang, J., Wang, Z., & Zhang, J. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.002 · Cited by 40
Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
Tian, T., Yu, M., Li, J., Jiang, M.-Q., Ma, D., Tang, S., Lin, Z., Chen, L., Gong, Y., Zhu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739090 · Cited by 32
Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
Miao, K., Zhang, X.-T., Wang, H.-P., Si, X., Ni, J., Zhong, W., Zhao, J., Xu, Y., Chen, M., Pan, R.-L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859938 · Cited by 28
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Li, H., Zhang, Y., Xu, Y., Huang, Z., Cheng, G., Xie, M., Zhou, Z., Yu, Y., Xi, W., & Fan, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05510-4 · Cited by 33
Efficacy of PD ‐1/ PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
Sheng, J., Li, H., Yu, X., Yu, S., Chen, K., Pan, G., Xie, M., Li, N., Zhou, Z., & Fan, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14171 · Cited by 28
m6A-mediated upregulation of lncRNA-AC026356.1 promotes cancer stem cell maintenance in lung adenocarcinoma via activating Wnt signaling pathway
Zhang, Z., Tan, X., Wu, R., Deng, T., Wang, H., Jiang, X., Zeng, P., & Tang, J. (2023) · Aging · doi:10.18632/aging.204689 · Cited by 33
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 31
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Soo, R. A., de Marinis, F., Han, J., Ho, J., Martin, E. C., Servidio, L., Sandelin, M., & Popat, S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.09.005 · Cited by 28
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Wiest, N. E., Majeed, U., Seegobin, K., Zhao, Y., Lou, Y., & Manochakian, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751209 · Cited by 26
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr -Mutant Lung Cancer
Nishii, K., Ohashi, K., Tomida, S., Nakasuka, T., Hirabae, A., Okawa, S., Nishimura, J., Higo, H., Watanabe, H., Kano, H., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0751 · Cited by 26
Exosome-Based Liquid Biopsy in Early Screening and Diagnosis of Cancers
Hao, X., Liu, Z., Ma, F., Li, T., Liu, C., Wang, N., Guan, J., He, N., Liu, J., Lu, S., et al. (2025) · Dose-Response · doi:10.1177/15593258251344480 · Cited by 24
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Borgeaud, M., Olivier, T., Bar, J., Saw, S. P. L., Parikh, K., Banna, G. L., Vito, C. D., Feldman, J., Le, X., & Addeo, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70024 · Cited by 34
Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma
Li, F., Wu, H., Du, X., Sun, Y., Rausseo, B. N., Talukder, A. H., Katailiha, A. S., Elzohary, L., Wang, Y., Wang, Z., et al. (2023) · Vaccines · doi:10.3390/vaccines11091460 · Cited by 23
Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling
Li, K., Mao, S., Li, X., Zhao, H., Wang, J., Wang, C., Wu, L., Zhang, K., Yang, H., Jin, M., et al. (2023) · Cancer Science · doi:10.1111/cas.15721 · Cited by 20
Self-citation
EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment
Chen, Q., Xia, L., Wang, J., Zhu, S., Wang, J., Li, X., Yu, Y., Li, Z., Wang, Y., Zhu, G., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107815 · Cited by 18
Self-citation
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
Vathiotis, I. A., Bafaloukos, D. I., Syrigos, K. N., & Samonis, G. (2023) · Cancers · doi:10.3390/cancers15041286 · Cited by 18
miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in “driver gene-negative” non-small cell lung cancer via activating the Wnt/β-catenin signaling
Cen, W., Yan, Q., Zhou, W., Mao, M., Huang, Q., Lin, Y., & Jiang, N. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00848-z · Cited by 17
Targeted Degradation of EGFR Mutations via Self-Delivery Nano-PROTACs for Boosting Tumor Synergistic Immunotherapy
Wang, X., Yan, J., Zhao, Y., Li, S., Ma, Z., Duan, X., Wang, Y., Jiao, J., Gu, C., & Zhang, G. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c01103 · Cited by 17
Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application
Wang, R.-L., Liu, Z., Wang, T., Zhang, J., Liu, J., & Zhou, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1320244 · Cited by 16
Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC
Li, M., Zhang, Y., Fan, M., Ren, H. J., Chen, M., & Shi, P. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01133-4 · Cited by 15
Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians
Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01221-3 · Cited by 15
Comprehensive characterization of posttranscriptional impairment-related 3′-UTR mutations in 2413 whole genomes of cancer patients
Wei, W., Gao, W., Li, Q., Liu, Y., Chen, H., Cui, Y., Sun, Z. S., & Liu, Z. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00305-0 · Cited by 15
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Wang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., & He, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145128 · Cited by 15
Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
Zhao, G., Zhang, H., Xu, F., Lu, C., Zhu, Q., Grossi, F., Divisi, D., Ma, T., Gu, J., & Ge, D. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-871 · Cited by 15
The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer
Liu, L., Li, F., Zhao, J., Zhuo, X., Lai, J., Wang, J., Jiang, F., Xu, W., Luan, F., Lin, X., et al. (2023) · Journal of Cancer · doi:10.7150/jca.77199 · Cited by 15
Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics
Ritu, R., Chandra, P., & Das, A. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01201-2 · Cited by 15
Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
Dong, Y., Khan, L., & Yao, Y. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.06.004 · Cited by 14
Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
Lei, S., Xu, H., Li, H., Yang, Y., Xu, F., Li, J., Wang, Z., Xing, P., Hao, X., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15021 · Cited by 13
Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 13
Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
Chen, P., Yang, Q., Li, Y., Jing, X., & Chen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894656 · Cited by 13
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
Sayer, M. R., Mambetsariev, I., Lu, K., Wong, C. W., Duche, A., Beuttler, R., Fricke, J., Pharoan, R., Arvanitis, L. D., Eftekhari, Z., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1064169 · Cited by 13
Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer
Ye, W., Li, M., & Luo, K.-W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071788 · Cited by 14
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
Qiao, M., Zhou, F., Liu, X., Jiang, T., Wang, H., Jia, Y., Li, X., Zhao, C., Cheng, L., Chen, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005436 · Cited by 15
Self-citation
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR -Mutant Non–Small Cell Lung Cancer
Wang, S., Lai, J.-C., Li, Y., Tang, C., Lu, J., Han, M. S., Ye, X., Jia, L., Cui, W., Yang, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1817 · Cited by 12
Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
Chen, Q., Shang, X., Liu, G., Ma, X., Han, W., Wang, X., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931718 · Cited by 12
NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma
Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X. W., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02475-8 · Cited by 12
Self-citation
What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy
Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12
First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
Nie, N., Li, J., Zhang, J., Dai, J., Liu, Z., Ding, Z., Wang, Y., Zhu, M., Hu, C., Han, R., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134735 · Cited by 12
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
Ding, J., Ding, X., & Leng, Z. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2170879 · Cited by 11
Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes
Bai, M., Wu, L., Zhao, M., Jin, P., Liu, J., Wang, W., Gao, X., Wang, Y., Chong, W., Yu, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1431 · Cited by 11
Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
Cheng, Y., Yang, B., Ouyang, W., Chen, J., Zhang, W., Chen, G., Zhang, J., Yu, J., & Xie, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920047 · Cited by 11
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen
Liu, K.-J., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107933 · Cited by 11
Self-citation
Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
Hu, Y., Liu, S., Wang, L., Liu, Y., Zhang, D., & Zhao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202822 · Cited by 10
PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
Wang, S., Su, D., Chen, H., Lai, J.-C., Tang, C., Yu, L., Wang, Y., Yang, Y., Qin, M., Jia, L., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01317-2 · Cited by 10
A Novel Integrated Metabolism-Immunity Gene Expression Model Predicts the Prognosis of Lung Adenocarcinoma Patients
Chen, S., Duan, Y., Wu, Y., Yang, D., & An, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728368 · Cited by 10
ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
Zhang, W., Shang, X., Liu, G., Ma, X., Yang, R. R., Xia, H., Zhang, Y., Zheng, Q., Wang, X., & Liu, Y. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02279-2 · Cited by 9
Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction
Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03435-0 · Cited by 10
Self-citation
Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies
Li, Y. L., YU, L., ZHOU, S., Zhou, H., & Wu, Q. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.059311 · Cited by 10
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study ( HOT2101 )
Tsuji, K., Mizugaki, H., Yokoo, K., Kobayashi, M., Kawashima, Y., Kimura, N., Yokouchi, H., Kikuchi, H., Sumi, T., Kawai, Y., et al. (2024) · Cancer Science · doi:10.1111/cas.16094 · Cited by 9
Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023
Huang, Z., Xie, T., Xie, W., Chen, Z., Wen, Z., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428018 · Cited by 10
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells
Nakagawa, N., Miyake, N., Ochi, N., Yamane, H., Takeyama, M., Nagasaki, Y., Ikeda, T., Yokota, E., Fukazawa, T., Nakanishi, H., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112940 · Cited by 8
Prediction of EGFR mutation status and its subtypes in non-small cell lung cancer based on 18F-FDG PET/CT radiological features
Fan, Y., Liu, Y., Ouyang, X., Su, J., Zhou, X., Jia, Q., Chen, W., Chen, W., & Liu, X. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001948 · Cited by 7
Self-citation
Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer
Joshi, H., & Sheikh, M. S. (2025) · Cancers · doi:10.3390/cancers17172791 · Cited by 7
From gene editing to tumor eradication: The CRISPR revolution in cancer therapy
Ali, A., Azmat, U., Khatoon, A., Akbar, K., Murtaza, B., Ji, Z., Irshad, U., & Su, Z. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.04.003 · Cited by 10
Integration of single-cell and bulk RNA-seq to establish a predictive signature based on the differentiation trajectory of M2 macrophages in lung adenocarcinoma
Chen, Z., Yang, J., Li, Y., Zeng, W., Bai, Y., Ding, C., Xu, C., Li, C., Chen, J., Ju, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1010440 · Cited by 7
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Choi, D.-H., Jung, H. A., Park, S., Sun, J., Ahn, J. S., Ahn, M., & Lee, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-643 · Cited by 7
Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma
Gong, Z., Wu, X., Guo, Q., Du, H., Zhang, F., & Kong, Y. (2022) · Genes · doi:10.3390/genes13071282 · Cited by 7
Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines
Tu, Y., Yeh, W., Fang, Y., Lo, K., Liang, L., Liu, X.-C., Tsai, C., Cheng, C., Lin, M., Yu, H., et al. (2025) · Experimental Physiology · doi:10.1113/ep092791 · Cited by 6
Self-citation
SNHG16-loaded extracellular vesicles from hypoxic NSCLC cells drive M2 macrophage polarization to enhance cancer aggressiveness
Hou, Y., Li, X., Zeng, L., & Zhang, Y. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.08.022 · Cited by 6
Self-citation
Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers
Shang, X., Geng, X., Wang, Z., Yuan, S., Ding, S., Liu, G., Ma, X., Sun, X., Wang, H., Sun, Y. H., et al. (2025) · Advanced Science · doi:10.1002/advs.202513182 · Cited by 6
Immunotherapy in EGFR-mutant non-small cell lung cancer
Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
Kuribayashi, T., Ohashi, K., Nishii, K., Ninomiya, K., Tsubata, Y., Ishikawa, N., Kodani, M., Kanaji, N., Yamasaki, M., Fujitaka, K., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05618-4 · Cited by 6
Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition)
Hao, X., The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association, & The Lung Cancer Expert Group of Chinese Medical Association Publishing House (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003055 · Cited by 6
Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy
Liao, W., Huang, S., Lin, L., Wang, J., Li, J., Chen, Y., Chen, L., Lian, Y., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers15010109 · Cited by 6
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
Hata, T., Sakaguchi, C., Hirano, K., Kobe, H., Ishida, M., Nakano, T., Tachibana, Y., Tamiya, N., Shiotsu, S., Takeda, T., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14836 · Cited by 6
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
Li, Y., Jiang, H., Qian, F., Chen, Y., Zhou, W., Zhang, Y., Lü, J., Lou, Y., Han, B., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161718 · Cited by 6
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6
Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report
Wu, Z., Zhang, Z., Zhang, D., & Li, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357230 · Cited by 6
Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study
Zhang, D., Liu, G., Ye, J., Li, K., Zhang, G., Quan, Q., Zhu, X., & Peng, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-13497-2 · Cited by 5
Targeting IL-6/STAT3 signaling to mitigate sarcopenia: Insights from immuno-metabolic crosstalk in NSCLC
Kumar, G., Khandibharad, S., & Singh, S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152727 · Cited by 5
An effective prognostic model for assessing prognosis of non-small cell lung cancer with brain metastases
Wang, R., Zhang, X. Y., He, C., & Guo, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1156322 · Cited by 5
Implication of PD‑L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD‑1 blockades: A retrospective exploratory study
Gong, Q., Qie, H., Dong, S.-Y., & Jiang, H. (2024) · Oncology Letters · doi:10.3892/ol.2024.14277 · Cited by 5
Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach
Zhang, X., Qiu, X., Zhang, Y., Lai, Q., Zhang, G., & Zhang, G. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00824-w · Cited by 5
EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?
Hofman, P. M. (2021) · Cells · doi:10.3390/cells10082157 · Cited by 5
Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment
Chen, J., Lv, B., Zhan, Y., Zhu, K., Zhang, R., Chen, B., Jin, Y., Li, Y., Zheng, J., & Lin, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.724261 · Cited by 5
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs
Cai, R., Liu, Y., Yu, M., Sha, H., Guo, M., Chen, Y., Ye, J., Zhou, G., Fang, Y., & Shen, B. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03570-9 · Cited by 5
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
González‐Cao, M., Cai, X., Bracht, J. W. P., Han, X., Yang, Y., Pedraz‐Valdunciel, C., Morán, T., García-Corbacho, J., Aguilar, A., Bernabé, R., et al. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s455034 · Cited by 5
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter, Z., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s443099 · Cited by 5
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
Zhu, L., He, W., Xie, C., Yang, S., Zhang, C., & Zhu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512468 · Cited by 4
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
Fujisaki, T., Miyauchi, E., Kida, G., Miura, Y., Watanabe, K., Ashinuma, H., Tamiya, M., Kikuchi, H., Arai, D., Takahashi, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108597 · Cited by 4
The Prognostic Role of Tertiary Lymphoid Structures and Immune Microenvironment Signatures in Early-Stage EGFR-Mutant Lung Adenocarcinoma
Hsu, W.-H., Hsu, C., Hsieh, M., & Yang, J. C. (2025) · Cancers · doi:10.3390/cancers17142379 · Cited by 4

Authors: Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., & Zhou, C.
Affiliations: Tongji University (CN)
Corresponding author: Zhou, Caicun
ORCID: Qiao, Meng
Jiang, Tao
Liu, Xinyu
Mao, Shiqi
Zhou, Fei
Li, Xuefei
Zhao, Chao
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-08
Volume: 16
Issue: 8
Pages: 1267-1288
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2021.04.003
OpenAlex: W3159640891
Cited by: 186
References: 184
Citations by year: 2026: 24 · 2025: 39 · 2024: 39 · 2023: 35 · 2022: 35 · 2021: 14
FWCI: 3.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (81871865, 81972167)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, PD-1/PD-L1 axis, predictive biomarkers, tumor mutational burden, PD-L1 expression, tumor microenvironment, immune cell infiltration, cytokines, combination immunotherapy, treatment response
MeSH terms: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Biomarkers, Tumor, Tumor Microenvironment, B7-H1 Antigen, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks